Nu Skin (NUS) Stock Sinks After Impairment Fueled Loss Deepens

Nu Skin Enterprises stock dropped about 5% today, adding to a rough three month stretch, yet the headline from this quarter is not the share price slide. The real story is a sharp reported loss driven by heavy non cash hits, including a goodwill impairment and a large valuation allowance on U.S. deferred tax assets, on top of only roughly flat revenue at about US$320 million. In other words, the market is reacting to broken earnings optics, while the longer term debate now centers on whether these charges reset the profit base or signal deeper balance sheet strain.

Concerned that Nu Skin Enterprises is wrestling with non cash charges and a messy reported loss and want stocks where the balance sheet and fundamentals look cleaner? Take a look at our list of solid balance sheet and fundamentals stocks (48 results).

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$320.1 million vs. US$386.1 million (revenue declined 17.1%)
• Net Income, Q2 2026 vs. Q2 2025: loss of US$249.8 million vs. profit of US$21.1 million (swing to a large loss driven by non cash charges)
• Basic EPS, Q2 2026 vs. Q2 2025: loss of US$5.14 per share vs. earnings of US$0.43 per share (earnings per share moved from profit to a sizeable loss)
• Gross Margin, Q2 2026 vs. Q2 2025: 68.2% overall, with core Nu Skin gross margin at 77.7% and up 0.2 percentage points year on year

Prefer clean charts over another wall of earnings tables and footnotes? See Nu Skin Enterprises’ full financial picture, including a clear view of its recent reported loss and balance sheet items, in an easy visual format via our company report for Nu Skin Enterprises.

Nu Skin bullish story leans on margins and cash

For a positive Nu Skin angle, focus on resilience rather than growth. Core Nu Skin gross margin sits at 77.7%, slightly higher year on year, which suggests the product mix and pricing power are holding up even with revenue at US$320.1 million. Adjusted EPS landed within guidance and an adjusted operating margin of 6.1% still leaves room to absorb field investments. The business also generated US$10.6 million of operating cash flow and holds cash broadly in line with debt, which supports the idea of a functioning consumer platform rather than a distressed balance sheet.

Nu Skin bear case sharpened by impairments and revenue drop

The cautious story around Nu Skin also finds plenty of support. Revenue fell 17.1% year on year to US$320.1 million and adjusted operating margin slipped from 8.0% to 6.1%, which points to pressure on scale and profitability. The reported loss of US$249.8 million, driven by goodwill impairment and a large tax valuation allowance, reinforces questions about growth prospects in parts of the business. The share price has fallen around 22% over 90 days and the updated guidance brackets Q3 and full year adjusted EPS at modest levels, which keeps execution risk front and center.

After a dividend that is not well covered and a sharp swing to a reported loss, review our risk analysis for Nu Skin Enterprises which shows 1 important warning sign.

Stay Ahead With Simply Wall St

If Nu Skin Enterprises has your attention after its sharp reported loss and heavy non cash charges, register for free with Simply Wall St and add it to a Watchlist to track share price moves against fair value and watch for a cleaner entry point. Once you decide to own the stock, use the Portfolio Command Center to keep your holdings organised and surface only the most critical updates that cut through market noise. For a broader view on Nu Skin Enterprises and other stocks, turn to the Community to see how different investors are thinking about the same data. This helps you spot potential catalysts and risks early so you can stay ahead of the market.

Curious About Alternatives Beyond Nu Skin

Fresh stock ideas can gain breakout momentum fast and then slip once the crowd catches on. Scan curated picks under the radar for now and act now.

• Spot companies quietly building strength before momentum is obvious by checking a curated 83 resilient stocks with low risk scores that keeps downside risk front of mind while you hunt for upside.
• Target potential future leaders in automation by scanning a focused set of 37 robotics and automation stocks that aim to ride real world adoption rather than hype that is already fading.
• Zero in on potential income workhorses by reviewing a carefully selected group of 9 dividend fortresses that aim to pair higher yields with sturdier fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com